• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. EU Approves AstraZeneca Pulmonary Disease Inhaled Treatment

    EU Approves AstraZeneca Pulmonary Disease Inhaled Treatment

  2. AstraZeneca Prices EUR750 Million Bonds

    AstraZeneca Prices EUR750 Million Bonds

  3. AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting

    AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting

  4. AstraZeneca Raises Earning Guidance for 2014 Despite Slide in Profits

    AstraZeneca Raises Earning Guidance for 2014 Despite Slide in Profits

  5. AstraZeneca Raises Earning Guidance for 2014

    AstraZeneca Raises Earning Guidance for 2014

  6. AstraZeneca and Amgen Skin Disease Treatment Succeeds in Trial

    AstraZeneca and Amgen Skin Disease Treatment Succeeds in Trial

  7. ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium

    ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium

  8. AstraZeneca Forecasts Annual Revenue of $45 Billion by 2023 -- Update

    AstraZeneca Forecasts Annual Revenue of $45 Billion by 2023 -- Update

  9. AstraZeneca Forecasts Annual Revenue of $45 Billion by 2023

    AstraZeneca Forecasts Annual Revenue of $45 Billion by 2023

  10. U.K. stocks fall after Japan GDP shock; AstraZeneca drops

    U.K. stocks fall after Japan GDP shock; AstraZeneca drops

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.